Return to List

Study Summary
No. ID00-230:.......Cancer Prevention; Lung......Jonathan M. Kurie......Thoracic and Head and Neck Med
.
Study Summary Title
Study Summary
Number:
ID00-230
Study Title:A Randomized, Double-Blind Study of the Biological Effects and Tolerability of Celecoxib as a Chemopreventive Agent in Current and Former Smokers
.
Physician New Patient Referral
Name:Jonathan M. KuriePatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:Thoracic and Head and Neck MedReferring MD
Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-792-6363
Contact us about clinical trials
.
General Information
Disease Group:Cancer Prevention
Lung
Supported By:N/A
Phase of Study:Phase IIReturn
Visit:
Patients will return to M.D. Anderson every month for 6 months.
Treatment
Agents:
Celecoxib
Placebo
Home Care:None.
Treatment Loc:Only at MDACC
Estimated
Length of Stay
in Houston:
N/A
Description/
Intervention:
The goal of this clinical research study is to learn if Celecoxib (Celebrex®)
can help prevent lung cancer. Scientists also want to see what effect Celecoxib
has on the cells of the body. The safety of Celecoxib dosages will also be
studied.
.
Study Objectives / Outcomes
· To examine the effect of celecoxib treatment on Ki-67 expression, a marker of cell proliferation, in the bronchial epithelium of current and former smokers.
· To examine the toxicity associated with celecoxib administration.
· To measure the effect of celecoxib treatment on arachidonic acid metabolites in the bronchial epithelium of current and former smokers.
.
Study Status Information
Study Activation / Registration Date:11/12/2001
IRB Review and Approval Date:09/06/2000
Study Type:Therapeutic
Recruitment Status:Terminated
Projected Accrual:250
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.

Inclusion Criteria:1) Participants must be 18-74 years old.

2) Participants must have at least a 20 pack-year history of smoking.

3) Participants may have had a prior laryngeal cancer (Stage I or II) that was completely resected or rendered disease-free by radiation therapy, or a prior lung cancer (Stage I NSCLC) that was completely resected, without radiotherapy. Participants must have been clinically free of any cancer for at least 6 months.

4) Participants must have no contraindications for undergoing bronchoscopy.

5) Participants must have no active pulmonary infections.

6) Participants must not be taking inhaled steroids or oral non-steroidal anti-inflammatory drugs on a regular basis. (Low dose aspirin <= 81 mg/day is allowed.)

7) Participants must have the following blood levels: total granulocyte count > 1500; platelet count > 100,000; total bilirubin <= 1.5 mg %; and creatinine <= 1.5 mg %.

8) Participants must complete the pretreatment evaluation and must consent to bronchoscopy and to endobronchial biopsy for documentation of histologic status.

9) Participants must sign a study-specific informed consent form.

Exclusion Criteria:1) Participants with active gastric or duodenal ulcers or a history of ulcers requiring prophylactic H2 blockers.

2) Participants with active pulmonary infections or recent history of pulmonary infection (within 1 month).

3) Participants receiving inhaled steroid therapy on a regular basis.

4) Participants with acute intercurrent illness, or participants who had surgery within the preceding 4 weeks unless they have fully recovered.

5) Participants requiring chronic ongoing treatment with NSAIDs.

6) Participants who are allergic to aspirin or sulfanamides.

7) Participants with history of stroke, transient ischemic attack, uncontrolled hypertension, and/or angina pectoris.

8) Participants who are pregnant and/or breast-feeding.

9) Participants (men or women) of childbearing potential who are not using an effective method of contraception.

10) History of cardiovascular diseases that might include one of the following: myocardial infarction, angina, coronary angioplasty, congestive heart failure, stroke, or coronary bypass surgery.

11) Diagnosis of diabetes

12) History of deep venous thrombosis, pulmonary embolism, systemic lupus erythermatous, family history of protein S or C deficiencies, prior heparin-induced thrombocytopenia, or known Factor V Leiden mutation.

13) Family history of premature CAD. This is defined as individuals with either: 1) father with MI prior to age 55, or 2) mother with MI prior to age 60.

.
Links
Registration Number: NCT00981201
Study Information on Clinical Trials Registry (clinicaltrials.gov)

Other Links:
.
Results


Return to Clinical Trials at M.D. Anderson Cancer Center